Skip to main content
SpringerLink
Log in

Issues in Translation of Pharmacogenomics into Clinical Practice

  • Chapter
  • First Online:
Pharmacogenomic Testing in Current Clinical Practice

Part of the book series: Molecular and Translational Medicine ((MOLEMED))

  • 997 Accesses

Abstract

Clinical laboratory tests are commonly used for supporting the diagnosis and prognosis of a disease, monitoring the efficacy progress of therapeutic management decisions, and measuring the foreign toxins. Recent advances in genomics have resulted in the generation of new assay panels to support personalized drug therapy – this offers new opportunities for clinical laboratories to make important contributions to healthcare. Pharmacogenomics (PGx) is a recognized discipline within pharmacology that involves testing relevant human genes, whose products are involved with the inter-individual variability of a drug’s pharmacokinetics, pharmacodynamics, and human leukocyte antigen (HLA) system profile. The effective use of PGx testing promises to improve the therapeutic efficacy of drugs while reducing the incidence and severity of adverse drug effects, and drive the optimum drug selection for therapy.

Parts of this chapter was published in Wu et al. [12] with permission from Future Medicine Ltd., http://www.futuremedicine.com/loi/pgs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Spear, B. B., Heath-Chiozzi, M., & Huff, J. (2001). Clinical application of pharmacogenetics. Trends in Molecular Medicine, 7, 201–204.

    Article  CAS  PubMed  Google Scholar 

  2. Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998). Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. The Journal of the American Medical Association, 279, 1200–1205.

    Article  CAS  PubMed  Google Scholar 

  3. Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley T. J., et al. (2004). Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients. British Medical Journal, 329, 15–19.

    Article  PubMed  Google Scholar 

  4. Aspden, P., Wolcott, J., Bootman, J. L., & Cronenwett, R. L., (Eds.). (2007). Preventing medication errors: Committee on identifying and preventing medication errors. Washington: National Academic Press.

    Google Scholar 

  5. Mallal, S., Phillips, E., Carosi, G., Molina, J.-M., Workman, C., Tomazic, J., et al. (2008). HLA-B*5701 screening for hypersensitivity to abacavir. The New England Journal of Medicine, 358, 568–579.

    Article  PubMed  Google Scholar 

  6. Chung, W. H., Hung S. I., Hong, H. S., Hsih, M. S., Yang, L. C., Ho, H. C., et al. (2004). Medical genetics: A marker for Stevens-Johnson syndrome. Nature, 428, 486–486.

    Article  CAS  PubMed  Google Scholar 

  7. Kalow, W. (1990). The pennsylvania state university college of medicine 1990 Bernard B. Brodie lecture: Pharmacogenetics: Past and future. Life Sciences, 47, 1385–1397.

    Article  CAS  PubMed  Google Scholar 

  8. Evans, D., Manley, K., & McKusick, V. (1960). Genetic control of isoniazid metabolism in man. British Medical Journal, 2, 485–491.

    Article  CAS  PubMed  Google Scholar 

  9. Weinshilboum, R. M., & Wang, L. (2006). Pharmacogenetics and pharmacogenomics: Development, science, and translation. Annual Review of Genomics and Human Genetics, 7, 223–245.

    Article  CAS  PubMed  Google Scholar 

  10. Collins, F. S., Morgan, M., & Patrinos, A. (2003). The human genome project: Lessons from large-scale biology. Science, 300, 286–290.

    Article  CAS  PubMed  Google Scholar 

  11. Vogel, F., & Jager, P. (1969). The genetic load of a human population due to cystostatic agents. Humangenetik, 7, 287–304.

    Article  CAS  PubMed  Google Scholar 

  12. Wu, A. H. B., Babic, N., & Yeo, K. T. J. (2009). Implementation of pharmacogenomics into the clinical practice of therapeutics: Issues for the clinician and the laboratorian. Personalized Medicine, 6, 315–327.

    Article  CAS  Google Scholar 

  13. Jensen, T. S., Jacques, L. B., Ciccanti, M., Long, K., Eggleston, L., & Roche, J. (2010). Proposed decision memo for pharmacogenomic testing to predict warfarin responsiveness. Accessed May 17, 2010, from http://www.cms.gov/mcd/viewdraftdecisionmemo.asp?from2=viewdraftdecisionmemo.asp&id=224&

  14. Wong, S. H., Happy, C., Blinka, D., Gock, S., Jentzen, J. M., Donald, Hon. J., et al. (2010). From personalized medicine to personalized justice: The promises of translational pharmaco­genomics in the justice system. Pharmacogenomics, 11(6), 731–737.

    Google Scholar 

  15. Rosenberg, Y., & Schron, E. (2010). Clarification of optimal anticoagulation through genetics (COAG); A randomized, multicenter, double-blind clinical trial to evaluate efficacy in the use of clinical plus genetic information to guide warfarin therapy initiation and improve anticoagulation control for patients. Accessed May 15, 2010, from http://coagstudy.org

  16. Meltzer, D. O., & Marlow E. (2010). Clinical and economic implications of genetic testing for warfarin management. Accessed May 15, 2010, from http://www.clinicaltrialssearch.org/clinical-and-economic-implications-of-genetic-testing-for-warfarin-management-nct00964353.html

  17. Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Meneveau, N., et al. (2009). Genetic determinants of response to clopidogrel and cardiovascular events. The New England Journal of Medicine, 360, 363–375.

    Article  CAS  PubMed  Google Scholar 

  18. Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., et al. (2009). Cytochrome P-450 polymorphisms and response to clopidogrel. The New England Journal of Medicine, 360, 354–362.

    Article  CAS  PubMed  Google Scholar 

  19. U.S. Food and Drug Administration (2010). Reduced effectiveness of plavix (clopidogrel) in patients who are poor metabolizers of the drug. Accessed May 15, 2010, from http://www.fda.gov/drugs/drugsafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm

  20. Epstein, R. S., Moyer, T. P., Aubert, R. E., O’Kane, D. J., Xia, F., Verbrugge, R.R., et al. (2010). Warfarin genotyping reduces hospitalization rates. Journal of the American College of Cardiology, 55, 2804–2812http://newsblog.mayoclinic.org/2010/03/16/warfarin-genetic-test-cuts-hospital-admissions/

    Google Scholar 

  21. The International Warfarin Pharmacogenetics C. (2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. The New England Journal of Medicine, 360, 753–764.

    Article  Google Scholar 

  22. Babic, N., Haverfield, E. V., Burrus, J. A., Lozada, A., Das, S., & Yeo, K. T. J. (2009). Comparison of performance of three commercial platforms for warfarin sensitivity genotyping. Clinica Chimica Acta, 406, 143–147.

    Article  CAS  Google Scholar 

  23. Valdes, R., Payne, D., & Linder, M. (2010). Laboratory Medicine Practice Guidelines. Laboratory analysis and application of pharmacogenetics to clinical practice. Accessed November 26, from http://www.aacc.org/members/nacb/LMPG/OnlineGuide/PublishedGuidelines/LAACP/Pages/default.aspx

  24. Centers for Disease Control and Prevention (2010). Genetic testing reference materials coordination program (GeT-RM). Accessed November 26, http://wwwn.cdc.gov/dls/genetics/rmmaterials/MaterialsAvailability.aspx

  25. Personalized Medicine Coalition. Accessed May 15, 2010, from http://www.personalizedmedicinecoalition.org/

  26. Roden, D. M., Altman, R. B., Benowitz, N. L., Giacomini, K. M., Johnson, J. A., Krauss, R. M., et al. (2006). Pharmacogenomics: Challenges and opportunities. Annals of Internal Medicine, 145, 749–757.

    PubMed  Google Scholar 

  27. Wilkinson, G. R. (2005). Drug metabolism and variability among patients in drug response. The New England Journal of Medicine, 352, 2211–2221.

    Article  CAS  PubMed  Google Scholar 

  28. Bolonna, A. A., Arranz, M. J., Mancama, D., & Kerwin, R. W. (2004). Pharmacogenomics – can genetics help in the care of psychiatric patients? International Review of Psychology, 16, 311–319.

    Article  CAS  Google Scholar 

  29. Yong, W. P., & Innocenti, F. (2007). Translation of pharmacogenetic knowledge into cancer therapeutics. Clinical Advances in Hematology & Oncology, 5, 698–706.

    Google Scholar 

  30. Carlquist, J. F. (2007). Cardiovascular therapy and pharmacogenetics in 2007. Pharmacogenomics, 8, 21–23.

    Article  PubMed  Google Scholar 

  31. Giacomini, K. M., Brett, C. M., Altman, R. B., Benowitz, N. L., Dolan, M. E., Flockhart, D. A., et al. (2007). The Pharmacogenetics Research Network: From SNP discovery to clinical drug response. Clinical Pharmacology and Therapeutics, i 81, 328–345.

    Article  CAS  PubMed  Google Scholar 

  32. Pharmacogenomics knowledge base. Accessed May 17, 2010, from http://www.pharmgkb.org/

  33. Altman, R., Schwartz, D., Berlin, D., Mittal, A., Person, M., Oppezzo, M., et al. (2010). DNA twist – A web-based tool of pharmacogenomics. Accessed May 17, 2010, from http://www.dnatwist.org/BDE/index.html

  34. Berlin, D. S., Person, M. G., Mittal, A., Oppezzo, M. A., Chin, D. B., Starr, B., et al. (2010). DNATwist: a Web-based tool for teaching middle and high school students about pharmaco­genomics. Clinical Pharmacology and Therapeutics, 87, 393–395.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Pritzker School of Medicine, University of Chicago, 5841 South Maryland Avenue, Chicago, IL, 60637, USA

    Kiang-Teck J. Yeo

Authors
  1. Kiang-Teck J. Yeo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nikolina Babic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alan H. B. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kiang-Teck J. Yeo .

Editor information

Editors and Affiliations

  1. San Francisco General Hospital, Clinical Chemistry Lab., University of California, San Francisco, 1001 Potrero Ave., San Francisco, 94110, California, USA

    Alan H. B. Wu

  2. Department of Pathology, Clinical Pharmacogenomics Program, University of Chicago, S. Maryland Ave. 5841, Chicago, 60637, Illinois, USA

    Kiang-Teck J. Yeo

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Yeo, KT.J., Babic, N., Wu, A.H.B. (2011). Issues in Translation of Pharmacogenomics into Clinical Practice. In: Wu, A., Yeo, KT. (eds) Pharmacogenomic Testing in Current Clinical Practice. Molecular and Translational Medicine. Humana Press. https://doi.org/10.1007/978-1-60761-283-4_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-283-4_1

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-282-7

  • Online ISBN: 978-1-60761-283-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation